Actively Recruiting

Phase 2
Phase 3
Age: 18Years +
All Genders
NCT07155187

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Led by AbbVie · Updated on 2026-03-11

430

Participants Needed

53

Research Sites

246 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan compared to standard of care (SOC). Telisotuzumab adizutecan is an investigational drug being developed for the treatment of NSCLC. This study will be divided into two stages, in the first stage (phase 2) participants will receive 1 of 2 doses of telisotuzumab adizutecan. In the second stage (phase 3) participants will receive the recommended phase 3 dose (RP3D) of telisotuzumab adizutecan, from the previous stage, or SOC. Approximately 430 adult participants with NSCLC will be enrolled in the study in 200 sites around the world. In phase 2, participants will receive 1 of 2 intravenous (IV) doses of telisotuzumab adizutecan. In phase 3, participants will receive the IV RP3D of telisotuzumab adizutecan, or SOC. The study will run for a duration of approximately 69 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

CONDITIONS

Official Title

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Histologically or cytologically confirmed locally advanced or metastatic non-squamous non-small cell lung cancer with EGFR Exon 19 deletion or Exon 21 L858R mutation
  • Provide archived or recent tumor tissue during screening
  • Received one prior third-generation EGFR TKI therapy and had documented disease progression after treatment
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1
  • At least one measurable lesion per RECIST version 1.1 that has not been previously irradiated
  • Clinically asymptomatic or stable central nervous system metastasis after treatment
  • Progression must have occurred during treatment if prior EGFR TKI was given as adjuvant therapy
Not Eligible

You will not qualify if you...

  • Tumors with adenosquamous, squamous histology, or sarcomatoid features
  • Received more than one line of systemic therapy in the locally advanced or metastatic setting
  • Presence of clinically significant medical conditions or other reasons interfering with participation
  • Current, past, or suspected interstitial lung disease or pneumonitis requiring steroids

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 53 locations

1

Highlands Oncology Group - Springdale /ID# 277132

Springdale, Arkansas, United States, 72762

Actively Recruiting

2

Cancer Care Centers of Brevard- Rockledge /ID# 277853

Rockledge, Florida, United States, 32955

Actively Recruiting

3

HealthPartners Cancer Research Center /ID# 277339

Saint Louis Park, Minnesota, United States, 55426

Actively Recruiting

4

Nho - Revive Research Institute /ID# 277569

Lincoln, Nebraska, United States, 68506

Actively Recruiting

5

Astera Cancer Care /ID# 277570

East Brunswick, New Jersey, United States, 08816-4096

Actively Recruiting

6

Tennessee Cancer Specialists - Knoxville - Old Weisgarber Road /ID# 277891

Knoxville, Tennessee, United States, 37909

Actively Recruiting

7

SCRI Oncology Partners /ID# 276959

Nashville, Tennessee, United States, 37203

Actively Recruiting

8

Northwest Cancer Specialists - Vancouver /ID# 277855

Vancouver, Washington, United States, 98684

Actively Recruiting

9

Canberra Hospital /ID# 277166

Garran, Australian Capital Territory, Australia, 2605

Actively Recruiting

10

St George Hospital /ID# 277168

Kogarah, New South Wales, Australia, 2217

Actively Recruiting

11

Mater Hospital Brisbane /ID# 276985

South Brisbane, Queensland, Australia, 4101

Actively Recruiting

12

Icon Cancer Centre Hobart /ID# 277549

Hobart, Tasmania, Australia, 7000

Actively Recruiting

13

St Vincent's Hospital Melbourne /ID# 277002

Fitzroy, Victoria, Australia, 03065

Actively Recruiting

14

Sunshine Hospital /ID# 276894

St Albans, Victoria, Australia, 3021

Actively Recruiting

15

One Clinical Research - Nedlands /ID# 277598

Nedlands, Western Australia, Australia, 6009

Actively Recruiting

16

Klinik Floridsdorf /ID# 276679

Vienna, State of Vienna, Austria, 1210

Actively Recruiting

17

Jessa Ziekenhuis - Campus Virga Jesse /ID# 277202

Hasselt, Limburg, Belgium, 3500

Actively Recruiting

18

Universitair Ziekenhuis Leuven /ID# 276874

Leuven, Vlaams-Brabant, Belgium, 3000

Actively Recruiting

19

Guangdong Provincial People'S Hospital /ID# 277631

Guangzhou, Guangdong, China, 510080

Actively Recruiting

20

Universitaetsklinikum Heidelberg /ID# 277275

Heidelberg, Baden-Wurttemberg, Germany, 69120

Actively Recruiting

21

Universitaetsklinikum Wuerzburg /ID# 277213

Würzburg, Bavaria, Germany, 97080

Actively Recruiting

22

Universitaetsklinikum Giessen und Marburg GmbH /ID# 276873

Marburg, Hesse, Germany, 35043

Actively Recruiting

23

Universitaetsklinikum Koeln /ID# 276862

Cologne, North Rhine-Westphalia, Germany, 50937

Actively Recruiting

24

Universitätsklinikum Jena /ID# 277281

Jena, Thuringia, Germany, 07747

Actively Recruiting

25

Meir Medical Center /ID# 277289

Kfar Saba, Central District, Israel, 4428164

Actively Recruiting

26

Rabin Medical Center /ID# 276748

Petah Tikva, Central District, Israel, 4941492

Actively Recruiting

27

Yitzhak Shamir Medical Center /ID# 276750

Ẕerifin, Central District, Israel, 7030000

Actively Recruiting

28

The Chaim Sheba Medical Center /ID# 276745

Ramat Gan, Tel Aviv, Israel, 5265601

Actively Recruiting

29

Rambam Health Care Campus- Haifa /ID# 276746

Haifa, Israel, 3525408

Actively Recruiting

30

Ospedale Isola Tiberina - Gemelli Isola /ID# 277117

Rome, Roma, Italy, 00186

Actively Recruiting

31

Istituto di Candiolo Fondazione del Piemonte per l'Oncologia IRCCS /ID# 277119

Candiolo, Torino, Italy, 10060

Actively Recruiting

32

Hokkaido University Hospital /ID# 277240

Sapporo, Hokkaido, Japan, 060-8648

Actively Recruiting

33

Kitasato University Hospital /ID# 277241

Sagamihara-shi, Kanagawa, Japan, 252-0375

Actively Recruiting

34

National Cancer Center Hospital /ID# 277093

Chuo-Ku, Tokyo, Japan, 104-0045

Actively Recruiting

35

Wakayama Medical University Hospital /ID# 277238

Wakayama, Wakayama, Japan, 641-8510

Actively Recruiting

36

Unidade Local de Saude do Alto Ave, EPE /ID# 277249

Guimarães, Braga District, Portugal, 4835-044

Actively Recruiting

37

Unidade Local de Saude de Loures-Odivelas, EPE /ID# 277223

Loures, Lisbon District, Portugal, 2674-514

Actively Recruiting

38

Unidade Local de Saude de Matosinhos, EPE /ID# 277228

Senhora da Hora, Porto District, Portugal, 4464-513

Actively Recruiting

39

Unidade Local de Saude de Braga, EPE /ID# 277217

Braga, Portugal, 4710-243

Actively Recruiting

40

Unidade Local de Saude de Santo Antonio, E.P.E. /ID# 277216

Porto, Portugal, 4099-003

Actively Recruiting

41

National Cancer Center /ID# 277353

Goyang-si, Gyeonggido, South Korea, 10408

Actively Recruiting

42

Chungbuk National University Hospital /ID# 277372

Cheongju-si, North Chungcheong, South Korea, 28644

Actively Recruiting

43

Seoul National University Hospital /ID# 277373

Seoul, Seoul Teugbyeolsi, South Korea, 03080

Actively Recruiting

44

Asan Medical Center /ID# 277371

Seoul, Seoul Teugbyeolsi, South Korea, 05505

Actively Recruiting

45

Samsung Medical Center /ID# 277600

Seoul, Seoul Teugbyeolsi, South Korea, 06351

Actively Recruiting

46

Hospital Universitario Virgen de la Victoria /ID# 277159

Málaga, Spain, 29010

Actively Recruiting

47

Hospital Clinico Universitario de Valencia /ID# 277147

Valencia, Spain, 46010

Actively Recruiting

48

Hospital Clinico Universitario Lozano Blesa /ID# 277154

Zaragoza, Spain, 50009

Actively Recruiting

49

Changhua Christian Hospital /ID# 277145

Changhua, Taiwan, 500

Actively Recruiting

50

Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 277138

Kaohsiung City, Taiwan, 807

Actively Recruiting

51

Taichung Veterans General Hospital /ID# 277142

Taichung, Taiwan, 407

Actively Recruiting

52

Mackay Memorial Hospital /ID# 277146

Taipei, Taiwan, 104

Actively Recruiting

53

Taipei Veterans General Hospital /ID# 277141

Taipei, Taiwan, 112

Actively Recruiting

Loading map...

Research Team

A

ABBVIE CALL CENTER

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here